Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Immutep Ltd.
If bad luck comes in threes, GSK will be delighted to see the end of this week with dostarlimab approval delayed, bintrafusp failing in lung cancer and a Phase II of an ulcerative colitis drug discontinued.
The US FDA tells manufacturers in two recent warning letters to get to the root cause of contamination problems and take a more proactive approach to cleaning and equipment maintenance.
Denmark’s biotech Genmab has dropped the AXL targeted antibody-drug conjugate, enapotamab vedotin from early clinical development, and is focusing its resources on other therapeutic programs.
Olema launched this year’s 75th US biopharma IPO. Also, investments in regenerative medicines reached a new high, Qiming closed a $1.2bn China-focused VC fund, D3 Bio led recent venture deals with a $200m round, and Bausch sold $2bn worth of notes to pay down near-term debts.
- Drug Delivery
- Gene Therapy, Cell Therapy
- Other Names / Subsidiaries
- Immutep S.A.S.
- Immutep GmbH
- Immutep, U.S., Inc.
- Prima BioMed Ltd.